Skip to content

A Analgesic Study of Adductor Canal &IPACK Block with Liposomal Bupivacaine in Knee Arthroplasty

A Analgesic Study of Adductor Canal &IPACK Block with Liposomal Bupivacaine in Knee Arthroplasty :A Randomized,Double-controlled,Parallel-controlled,Single-center Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06145165
Enrollment
90
Registered
2023-11-24
Start date
2023-12-10
Completion date
2024-12-31
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liposomal Bupivacaine, Postoperative Recovery, Unilateral Knee Arthroplasty

Brief summary

To study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty

Detailed description

The pain after knee arthroplasty limits the patient's activities and postoperative recovery, and currently there are mainly three analgesic methods: intravenous analgesia, epidural analgesia and nerve block analgesia. There is a lack of studies on whether liposomal bupivacaine, if used for ACB and iPACK block, can achieve benefits in knee arthroplasty pain management by prolonging sensory nerve block without affecting muscle strength, improving patient prognosis, and shortening hospitalization days. In this study, in order to better evaluate the effect of liposomal bupivacaine for ACB and iPACK biock on the prognosis of patients undergoing knee arthroplasty, not only the NRS and AUC of patients in each group will be observed, but also the postoperative QoR-15 Quality of Recovery Rating Scale, postoperative nausea, vomiting and other complications, and the number of hospitalization days will be also included as observation indicators. The completion of this study can provide a clinical basis for the selection of analgesic regimens for knee arthroplasty, and also provide strong evidence-based medical support for the relevant medical decision making of government departments.

Interventions

OTHERNerve block with ropivacaine and intravenous analgesia

When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

COMBINATION_PRODUCTNerve block with liposomal bupivacaine and intravenous analgesia

When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

Sponsors

Nanjing First Hospital, Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 18-79 years. 2. Patients undergoing unilateral total knee arthroplasty or unicondylar joint replacement. 3. Normal diet. 4. ASA grade I\ Ⅲ; 5. BMI 18-30kg /m2. 6. No intraspinal anesthesia contraindications.

Exclusion criteria

1. Patients with severe neurological diseases. 2. Hearing and speech impaired. 3. Preoperative gastric emptying disorders, such as gastrointestinal obstruction, gastroesophageal reflux, or previous gastrointestinal surgery, etc. 4. Patients with severe renal insufficiency or other severe metabolic diseases. 5. Mental disorders, alcoholism or a history of drug abuse. 6. The surgical time is greater than 3 hours. 7. Puncture site infection, abnormal coagulation function, and local anesthetic allergy.

Design outcomes

Primary

MeasureTime frameDescription
The cumulative use of analgesic drugs (sufentanil,calculated in ug)up to 48 hours postoperative in each groupUp to 48 hours postoperativeTo study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty.A lower dose of analgesics indicates a longer duration of block.

Secondary

MeasureTime frameDescription
The total number of PCIA compressions on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.Fewer total PCIA compressions indicated a longer duration of block.
The number of effective PCIA compressions on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.Fewer total effective PCIA compressions indicated a longer duration of block.
The number of times of remedial analgesia on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.Fewer times of rescue analgesia indicated a longer duration of analgesia.
The cumulative use of analgesic drugs (sufentanil,calculated in ug)on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.Less cumulative use of analgesics indicates a longer duration of block
NRS scores at rest and during exerciseat at 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours postoperativeat 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours postoperativeThe NRS typically consists of a straight line with numbers ranging from 0 to 10. Each number corresponds to a level of pain intensity:0: No pain.1 to 3: Mild pain (low intensity). 4 to 6: Moderate pain (moderate intensity). 7 to 10: Severe pain (high intensity) Patients are asked to choose a number that best represents their current pain level, where 0 means no pain, and 10 indicates the worst possible pain.A lower NRS score indicates a longer duration of block.
Satisfaction score of subjects on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.Rated on a 0-10 scale, with a higher score representing greater satisfaction.
Satisfaction score of surgeons on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.Rated on a 0-10 scale, with a higher score representing greater satisfaction.
Both the liposomal bupivacaine group and the ropivacaine group were subjected to ACB and iPACK block. Area under the pain intensity-time curve within 72 hours after the first postoperative dose(PI-AUC72)was observed in the three groups.within 72 hours after the first postoperative initiation of drug administrationA smaller PI-AUC72 indicates a longer duration of nerve block.
15-item Quality of Recovery Rating Scale (QoR-15): 24hours, 48hours and 72hours postoperativelyat 24 hours, 48 hours and 72 hours postoperativeQoR-15 was used to assess five aspects of postoperative recovery quality (physical comfort, physical independence, psychological support, emotion and pain), with higher scores indicating the higher postoperative recovery quality. The lowest score is 0 points, and the highest score is 150 points.
The percentage of subjects who did not use remedial analgesics on the first day,the second day and the third day after surgery.On the first day,the second day and the third day after surgery.A greater percentage of subjects who did not use rescue analgesics indicated a longer duration of analgesic block.

Countries

China

Contacts

Primary ContactLiu Han
han_cold.student@sina.com18951670163
Backup ContactYing Zhang
1070434273@qq.com15380998716

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026